US Congress overrides Medicare veto

20 July 2008

The US Congress has voted to override President George W Bush's veto of the Medicare Improvement for Patients and Providers Act of 2008 (HR 6331) in an unusual move. In order to do this, both the House of Representatives, with 383 votes to 41, and the Senate, 70 to 26, approved the blocked legislation by over two-thirds. A 10.6% cut in physician reimbursements under the Medicare program has now been scrapped, but a year-on-year expansion of end-stage renal disease care has been provided for under the HR 6331 Act.

According to analysts at Lehman Brothers, the switch to a bundled payment system and an annual update on dialysis service reimbursement is likely to benefit the manufacturers of related medical devices. However, Lehman's Ed Ridley-Day also noted that erythropoiesis-stimulating agents such as erythropoietin will be included in the federal program's expansion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight